Just In
- 1 min ago New Book ‘Kathmandu Chronicle: Reclaiming India-Nepal Relations’ To Shed Light On Geopolitical Uncertainties
- 4 hrs ago Russian Influencer Starves His Newborn To Death With Sunlight Diet, Know Dos And Don’ts Of This Diet
- 6 hrs ago Mahavir Jayanti 2024: Date, Time, History, Celebrations And Teachings Of Lord Mahavir In Jainism
- 7 hrs ago Parineeti Chopra Saree Looks: Check Amar Singh Chamkila Actor's Regal Fashion Statements
Don't Miss
- News FIR Filed Against DK Shivakumar Over Poll Code Violation
- Automobiles Ola Electric Hits New Milestone – 500th Service Centre Opened In Kochi
- Sports KKR vs RCB IPL 2024 Playing 11: Kolkata Knight Riders vs Royal Challengers Bengaluru Team News, Predicted Lineup
- Education Railway RPF Recruitment 2024; Apply Online for 4660 Post Vacancies @rpf.indianrailways.gov.in
- Movies Do Aur Do Pyaar Box Office Collection Day 2 Prediction: Vidya-Pratik's Rom-Com To Cross 1 Cr On Saturday
- Finance Elon Musk Postpones India Trip, Tesla's Indian Market Entry Delayed
- Technology Best Noise-Cancelling Earbuds Under Rs 5,000: CMF Buds Pro, Redmi Buds 5, Realme Buds Air 5, and More
- Travel Journey From Delhi To Ooty: Top Transport Options And Attractions
Novel Inhalable COVID-19 Vaccine Is Stable At Room Temperature: Study
Researchers in the US have developed an inhalable, self-administered COVID-19 vaccine that is shelf stable at room temperature for up to three months.
The team found that the delivery mechanism for this vaccine, a lung-derived exosome called LSC-Exo, is more effective at evading the lung's lining than the lipid-based nanoparticles currently in use. Exosomes are extracellular vesicles generated by all cells, and they carry nucleic acids, proteins, lipids and metabolites.
The research paper, published in the journal Nature Biomedical Engineering, describes the development of the vaccine prototype from proof-of-concept to animal studies, which can be used effectively with protein-based vaccines.
"An inhalable vaccine will confer both mucosal and systemic immunity, it is more convenient to store and distribute, and could be self-administered on a large scale," said Ke Cheng from the University of North Carolina at Chapel Hill, US."
So while there are still challenges associated with scaling up production, we believe that this is a promising vaccine worthy of further research and development, "he added.
There are several challenges associated with vaccine delivery that the researchers wanted to address. First, taking the vaccine via intramuscular shot is less efficient at getting it into the lung system, and so can limit its efficacy, the researchers said, adding that inhaled vaccines would increase its benefit against COVID-19.
Second, mRNA vaccines in their current formulation require cold storage and trained medical personnel to deliver them, they said. A vaccine that is stable at room temperature and that could be self-administered would greatly reduce wait times for patients as well as stress on the medical profession during a pandemic, according to the researchers.
However, reformulating the delivery mechanism is necessary for it to work through inhalation, they said. The researchers created and tested an inhalable, protein-based, virus-like particle (VLP) vaccine by decorating the exterior of LSC-Exo with a portion of the spike protein -- known known as the receptor binding domain, or RBD -- from the SARS-CoV-2 virus.
RBD is a short fragment from a virus that binds to a specific receptor to gain entry into host cells.
"Vaccines can work through various means. For example, mRNA vaccines deliver a script to your cell that instructs it to produce antibodies to the spike protein (which helps the virus to gain entry into a cell), "Cheng said.
"This VLP vaccine, on the other hand, introduces a portion of the spike protein to the body, triggering the immune system to produce antibodies to the spike protein," the scientist added.
- wellnessGap Between Second And Precaution Dose Of Covid-19 Vaccine Reduced To 6 Months
- wellnessNTAGI To Review Covaxin Corbevax Data For 6-12 Years Thursday, Discuss Reducing Booster Dose Gap
- wellnessEven Vaccinated People Can Develop Long Covid, Study Finds
- wellnessBooster Dose Of COVID Vaccine Needed To Fight Against Omicron: Study
- basicsNovavax's Covid-19 Vaccine Covovax Gets Emergency Use Authorisation For 12-17 Age Group In India
- wellnessAIIMS Delhi To Start Booster Dose Trial Of Intranasal Covid Vaccine From March 11
- wellnessDecision On COVID-19 Vaccine Precaution Dose For All Adults Will Be Based On Scientific Need: Govt
- healthIsrael To Administer Fourth Dose Of COVID-19 Vaccine For Medical Personnel And Senior Citizens
- healthHospital Launches Vaccination Programme For Children Aged 15-18 Yrs Across The Country
- healthSII Gets DCGI Nod To Manufacture Drug Substance, Test It For Developing Jab Against Omicron
- healthDecision On Which Vaccine To Be Given As Precautionary Dose Expected Soon: Govt
- healthIndia-US Healthcare Collaboration In Spotlight As India Approves Two More Covid-19 Vaccines